Eslam Elkhadrawy/LinkedIn
Jan 28, 2026, 11:45
Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
Eslam Elkhadrawy, Product Specialist at Inspire Pharma Egypt, shared on LinkedIn:
”Heparin-Induced Thrombocytopenia (HIT):
When anticoagulation paradoxically causes thrombosis
HIT is a severe immune-mediated adverse drug reaction in which heparin exposure leads to thrombocytopenia accompanied by a high risk of thrombosis, rather than bleeding.
The condition is driven by IgG antibodies against the heparin–platelet factor 4 (PF4) complex, resulting in platelet activation and excessive thrombin generation.
Key message:
In HIT, thrombocytopenia reflects platelet activation and consumption, not impaired hemostasis.
References
Greinacher A. NEJM, 2015
Warkentin TE. Circulation, 2015”
Stay updated with Hemostasis Today.
-
Jan 28, 2026, 13:55Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
-
Jan 28, 2026, 13:35Louise St Germain Bannon Invites You to Submit Your Work to JTH and RPTH
-
Jan 28, 2026, 13:26Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
-
Jan 28, 2026, 13:14Robert Campbell Congratulates Izabella Andrianova for Her Recent Publication in JTH
-
Jan 28, 2026, 12:59Pall Onundarson: Diluted Fiix Test Can Be Used to Measure DOACs
-
Jan 28, 2026, 12:06Gevorg Tamamyan On Transparency as the Foundation of Trust
-
Jan 28, 2026, 11:54Abdulrahman Katib on STORM-PE Results In Favour of Thrombectomy in PE
-
Jan 28, 2026, 11:38Arun V J: Why Does Only 3% Donate Blood Even Though 95% Believe Donating Is Essential?
-
Jan 28, 2026, 08:59Chris Jones: Quality Over Quantity is Definitely The Priority